AU2020357078A1 - Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics - Google Patents
Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics Download PDFInfo
- Publication number
- AU2020357078A1 AU2020357078A1 AU2020357078A AU2020357078A AU2020357078A1 AU 2020357078 A1 AU2020357078 A1 AU 2020357078A1 AU 2020357078 A AU2020357078 A AU 2020357078A AU 2020357078 A AU2020357078 A AU 2020357078A AU 2020357078 A1 AU2020357078 A1 AU 2020357078A1
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- composition
- nucleic acid
- sirna
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910760P | 2019-10-04 | 2019-10-04 | |
| US62/910,760 | 2019-10-04 | ||
| US201962915450P | 2019-10-15 | 2019-10-15 | |
| US62/915,450 | 2019-10-15 | ||
| PCT/US2020/054251 WO2021067930A1 (en) | 2019-10-04 | 2020-10-05 | Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020357078A1 true AU2020357078A1 (en) | 2022-05-26 |
Family
ID=75337467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020357078A Abandoned AU2020357078A1 (en) | 2019-10-04 | 2020-10-05 | Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220331441A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4037716A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7644105B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220110174A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115151278B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020357078A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022006473A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156823A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291916A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067930A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202204734B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7512207B2 (ja) * | 2018-05-24 | 2024-07-08 | サーナオミクス インコーポレイテッド | 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法 |
| CN118613484A (zh) * | 2021-12-30 | 2024-09-06 | 拜奥迪斯私人有限公司 | 抗叶酸剂接头-药物和抗体-药物缀合物 |
| CN120158469A (zh) * | 2025-05-19 | 2025-06-17 | 内蒙古大学 | 一种灌胃递送靶向编辑甲烷八叠球菌的牛甲烷减排方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10501963A (ja) * | 1994-04-15 | 1998-02-24 | ターゲテッド ジェネティクス コーポレイション | 遺伝子送達融合タンパク質 |
| EP1817416A2 (en) * | 2004-11-05 | 2007-08-15 | Intradigm Corporation | Compositions for treating respiratory viral infections and their use |
| EP1812016A4 (en) * | 2004-11-17 | 2010-07-14 | Univ Maryland | HIGH-BRANCHED HK-PEPTIDES AS EFFECTIVE CARRIER FROM SIRNA |
| ES2545963T3 (es) * | 2007-11-06 | 2015-09-17 | Sirnaomics, Inc. | Terapéutica con ARNi multidirigidos para la cicatrización de heridas de la piel sin cicatriz |
| CN102316858A (zh) * | 2008-02-26 | 2012-01-11 | 阿帕玛生物科技公司 | 修饰过的可调的纳米粒子用于传递治疗,诊断,实验化合物及相关成分用于治疗用药 |
| WO2010078517A2 (en) | 2008-12-31 | 2010-07-08 | Sirnaomics, Inc. | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer |
| WO2011011631A2 (en) * | 2009-07-22 | 2011-01-27 | Samuel Zalipsky | Nucleic acid delivery vehicles |
| US11058779B2 (en) * | 2015-09-08 | 2021-07-13 | Sirnaomics, Inc. | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection |
| CN107793388B (zh) * | 2016-10-14 | 2021-06-11 | 长沙天赐生物医药科技有限公司 | 平板霉素类似物及其制备方法和应用 |
| EP3532071A4 (en) * | 2016-10-30 | 2020-09-02 | Sirnaomics, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE TO ACTIVATE HUMAN FIBROBLAST AND MYOFIBROBLAST APOPTOSIS |
| JP7512207B2 (ja) | 2018-05-24 | 2024-07-08 | サーナオミクス インコーポレイテッド | 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法 |
| US20210180089A1 (en) * | 2018-08-14 | 2021-06-17 | Loxegen Holdings Pty Ltd | Nanoparticles for transfection |
| WO2021061437A1 (en) | 2019-09-12 | 2021-04-01 | Sirnaomics, Inc. | CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER |
-
2020
- 2020-10-05 KR KR1020227014303A patent/KR20220110174A/ko not_active Ceased
- 2020-10-05 IL IL291916A patent/IL291916A/en unknown
- 2020-10-05 JP JP2022520803A patent/JP7644105B2/ja active Active
- 2020-10-05 CN CN202080084185.2A patent/CN115151278B/zh active Active
- 2020-10-05 CA CA3156823A patent/CA3156823A1/en active Pending
- 2020-10-05 WO PCT/US2020/054251 patent/WO2021067930A1/en not_active Ceased
- 2020-10-05 EP EP20872228.0A patent/EP4037716A4/en not_active Withdrawn
- 2020-10-05 BR BR112022006473A patent/BR112022006473A2/pt not_active IP Right Cessation
- 2020-10-05 AU AU2020357078A patent/AU2020357078A1/en not_active Abandoned
-
2022
- 2022-04-04 US US17/713,037 patent/US20220331441A1/en active Pending
- 2022-04-28 ZA ZA2022/04734A patent/ZA202204734B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022550901A (ja) | 2022-12-05 |
| CN115151278B (zh) | 2025-08-22 |
| BR112022006473A2 (pt) | 2022-07-05 |
| WO2021067930A1 (en) | 2021-04-08 |
| EP4037716A4 (en) | 2023-05-03 |
| US20220331441A1 (en) | 2022-10-20 |
| CA3156823A1 (en) | 2021-04-08 |
| ZA202204734B (en) | 2024-09-25 |
| EP4037716A1 (en) | 2022-08-10 |
| IL291916A (en) | 2022-06-01 |
| JP7644105B2 (ja) | 2025-03-11 |
| KR20220110174A (ko) | 2022-08-05 |
| CN115151278A (zh) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100883471B1 (ko) | siRNA의 세포내 전달을 위한 siRNA와 친수성 고분자 간의접합체 및 그의 제조방법 | |
| Gooding et al. | Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis | |
| US20220331441A1 (en) | Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics | |
| US20070287681A1 (en) | siRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof | |
| Schroeder et al. | Alkane-modified short polyethyleneimine for siRNA delivery | |
| CN102027043A (zh) | 生物可降解的交联支链聚(亚烷基亚胺) | |
| JP2010526091A5 (cg-RX-API-DMAC7.html) | ||
| MXPA04005194A (es) | Compolimero soluble en agua policationico y metodo para transferir macromoleculas polianionicas a traves de barreras biologicas. | |
| JP2010526091A (ja) | 癌の処置のための生物学的な標的基の改変 | |
| KR101445265B1 (ko) | 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물 | |
| Tang et al. | Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT | |
| MX2012011515A (es) | Entidades quimicas simples novedosas y metodos de suministro de oligonucleotidos. | |
| WO2011154331A1 (en) | Polymers for delivery of nucleic acids | |
| WO2008042686A2 (en) | Multifunctional carriers for the delivery of nucleic acids and methods of use thereof | |
| WO1998046274A2 (en) | Cationic polymers for nucleic acid transfection | |
| Kano et al. | Grafting of poly (ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA | |
| CN114392358A (zh) | 一种肿瘤靶向的核酸适体药物偶连物 | |
| KR20220030204A (ko) | 치료 분자의 표적화된 전달 | |
| Zhang et al. | A zwitterionic polymer-inspired material mediated efficient CRISPR-Cas9 gene editing | |
| JP2022550901A5 (cg-RX-API-DMAC7.html) | ||
| MXPA01012802A (es) | Copolimeros para el transporte de acidos nucleicos a las celulas. | |
| CN102652836A (zh) | 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法 | |
| WO2022081911A1 (en) | Linker compounds comprising amide bonds | |
| Kos et al. | Gene transfer with sequence-defined oligo (ethanamino) amides bioreducibly attached to a propylenimine dendrimer core | |
| EP1280560A1 (en) | Cationic polymer-nucleic acid complexes and methods of making them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |